Literature DB >> 6683012

Protective effect of reduced glutathione against cis-dichlorodiammine platinum (II)-induced nephrotoxicity and lethal toxicity.

F Zunino, O Tofanetti, A Besati, E Cavalletti, G Savi.   

Abstract

Pretreatment of Swiss mice and Sprague-Dawley rats with glutathione (GSH) reduced the acute lethal toxicity of cis-dichlorodiammine platinum (II) (cis-DDP) in a dose-dependent manner. The protection was accompanied by reduction of both body weight loss and by reduction of nephrotoxicity, as measured by a rise in serum blood urea nitrogen (BUN), creatinine levels and by histopathologic changes, which occurred 4 days following cis-DDP treatment. The antitumor effects of cis-DDP on experimental tumor models (P388 and Gross leukemia) were not significantly altered by GSH treatment. It is suggested that the partial protection by GSH from acute toxicity of the antitumor drug is directly related to protection of renal function.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6683012     DOI： 10.1177/030089168306900204

Source DB:  PubMed          Journal:  Tumori        ISSN： 0300-8916


  6 in total

1.  Prevention of cyclophosphamide-induced urotoxicity by reduced glutathione and its effect on acute toxicity and antitumor activity of the alkylating agent.

Authors:  O Tofanetti; E Cavalletti; A Besati; G Pratesi; G Pezzoni; F Zunino
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

2.  Weekly 5-fluorouracil and folinic acid plus escalating doses of cisplatin with glutathione protection in patients with advanced head and neck cancer.

Authors:  V Gebbia; R Valenza; A Testa; G Zerillo; S Restivo; G Cupido; F Ingria; G Spadafora; C Barbaccia; G Cannata
Journal:  Med Oncol Tumor Pharmacother       Date:  1992

3.  The effect of treatment with high dose melphalan, cisplatin or carboplatin on levels of glutathione in plasma, erythrocytes, mononuclear cells and urine.

Authors:  L Hogarth; M English; L Price; R Wyllie; A D Pearson; A G Hall
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

4.  Efficacy and safety of high-dose cisplatin and cyclophosphamide with glutathione protection in the treatment of bulky advanced epithelial ovarian cancer.

Authors:  F Di Re; S Bohm; S Oriana; G B Spatti; F Zunino
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

5.  Influence of glutathione administration on the disposition of free and total platinum in patients after administration of cisplatin.

Authors:  R Leone; M E Fracasso; E Soresi; G Cimino; M Tedeschi; D Castoldi; V Monzani; L Colombi; T Usari; A Bernareggi
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

6.  Glutathione restores normal cell activation and cell cycle progression in cis-platinum treated human lymphocytes.

Authors:  M Kubbies; B Goller; B Schetters; I Bartosek; W Albert
Journal:  Br J Cancer       Date:  1991-11       Impact factor: 7.640
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.